The HEALEY ALS Platform Trial team is launching a new webinar series to enable members of the ALS community to learn about the mechanism of action and science behind each of the four drugs currently in testing in the Platform Trial. Each webinar in this series is dedicated to one of the currently enrolling Platform Trial drugs. Research scientists from the companies that developed these drugs will present the rationale and science behind their investigational treatment for ALS. During the webinars, attendees will have the opportunity to interact with the researchers who developed these drugs and submit questions live.

The webinars will be held on select Thursdays from 5:00-6:00 PM EST. Please see the schedule for the upcoming mechanism of action and science webinar series below. Registration is required and can be done on the Mass General Healey Center website by selecting the link next to the webinar you are interested in attending. There is no limit to the number of webinars you can attend, so please register in advance for as many as you wish. If you are unable to attend, recordings of these webinars will be made available in the "Previous Webinars" section on our website.

Drug Mechanism of Action and Science Webinar Schedule:

January 21: Prilenia Therapeutics Presents Pridopidine

February 4: Clene Nanomedicine Presents CNM-Au8

February 18: Biohaven Pharmaceuticals Presents Verdiperstat

February 25: UCB Presents Zilucoplan

Register for webinars